Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant
Conditions
Keywords
Tuberculosis, Multi Drug-Resistant Tuberculosis, Drug-sensitive Tuberculosis, PA-824, Moxifloxacin, Pyrazinamide, Rifampicin, Isoniazid, Ethambutol, HRZE, HR, Pretomanid, NC-006, STAND
Brief summary
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of moxifloxacin, PA-824, and pyrazinamide treatments with varying doses and treatment lengths from 4 to 6 months in subjects with drug-sensitive (DS) pulmonary TB compared to standard HRZE treatment. This study will also assess the efficacy, safety and tolerability of a combination of moxifloxacin, PA-824, and pyrazinamide treatments after 6 months of treatment in subjects with multi drug-resistant (MDR) pulmonary TB compared to a combination of moxifloxacin, PA-824, and pyrazinamide treatments in DS-TB subjects.
Interventions
DRUGMoxifloxacin
Oral
DRUGPA-824
Oral
DRUGPyrazinamide
Oral
DRUGHR (rifampicin plus isoniazid combination tablets)
Oral
Sponsors
Global Alliance for TB Drug Development
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures. 2. Male or female, aged 18 years or over. 3. Body weight (in light clothing and no shoes) ≥ 30 kg. 4. Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease (IUATLD) and World Health Organization (WHO) scale on smear microscopy at the trial laboratory. 5. Drug-Sensitive TB treatment arms subjects should be: * sensitive to rifampicin by rapid sputum based test (may be sensitive or resistant to isoniazid) AND * either newly diagnosed for TB or have a patient history of being untreated for at least 3 years after cure from a previous episode of TB. If they are entered into the trial due to being sensitive to rifampicin by rapid sputum based test, however on receipt of the rifampicin resistance testing using an indirect susceptibility test in liquid culture this shows they are rifampicin resistant, they will be: * Excluded as late exclusions; * Possibly replaced as determined by the sponsor. 6. MDR-TB treatment arm subjects should be resistant to rifampicin by rapid sputum based test (may be sensitive or resistant to isoniazid). 7. A chest x-ray which in the opinion of the investigator is compatible with pulmonary TB. 8. Be of non-childbearing potential or using effective methods of birth control, as defined below: Non-childbearing potential: * Subject - not heterosexually active or practice sexual abstinence; or * Female subject or male subjects female sexual partner - bilateral oophorectomy, bilateral tubal ligation and/or hysterectomy or has been postmenopausal with a history of no menses for at least 12 consecutive months; or * Male subject or female subjects male sexual partner - vasectomised or has had a bilateral orchidectomy minimally three months prior to screening; Effective birth control methods: * Double barrier method which can include a male condom, diaphragm, cervical cap, or female condom; or * Female subject: Barrier method combined with hormone-based contraceptives or an intra-uterine device for the female patient. * Male subjects' female sexual partner: Double barrier method or hormone-based contraceptives or an intra-uterine device for the female partner. and are willing to continue practising birth control methods and are not planning to conceive throughout treatment and for 12 weeks (male subjects) or 1 week (female subjects) after the last dose of trial medication or discontinuation from trial medication in case of premature discontinuation. (Note: Hormone-based contraception alone may not be reliable when taking IMP; therefore,
Exclusion criteria
1. Any non TB related condition (including myasthenia gravis) where participation in the trial, as judged by the investigator, could compromise the well-being of the subject or prevent, limit or confound protocol specified assessments. 2. Being or about to be treated for Malaria. 3. Is critically ill and, in the judgment of the investigator, has a diagnosis likely to result in death during the trial or the follow-up period. 4. TB meningitis or other forms of extrapulmonary tuberculosis with high risk of a poor outcome, or likely to require a longer course of therapy (such as TB of the bone or joint), as judged by the investigator. 5. History of allergy or hypersensitivity to any of the trial IMP or related substances, including known allergy to any fluoroquinolone antibiotic, history of tendinopathy associated with quinolones or suspected hypersensitivity to any rifampicin antibiotics. 6. For HIV infected subjects any of the following: * CD4+ count \<100 cells/µL; * Karnofsky score \<60%; * Received intravenous antifungal medication within the last 90 days; * WHO Clinical Stage 4 HIV disease. 7. Resistant to fluoroquinolones (rapid, sputum - based molecular screening tests). If they are entered into the trial due to being sensitive to fluoroquinolones by rapid sputum based test, however on receipt of the fluoroquinolones resistance testing using an indirect susceptibility test in liquid culture this shows they are fluoroquinolones resistant, they will be: * Excluded as late exclusions; * Possibly replaced as determined by the sponsor. 8. Resistant to pyrazinamide (rapid, sputum - based molecular screening tests). Drug-Sensitive TB treatment arms subjects may be entered prior to receipt of the rapid, sputum - based molecular pyrazinamide resistance screening test result. On receipt of the result, if they are resistant, they will be: * Excluded as late exclusions; * Possibly replaced as determined by the sponsor. MDR-TB treatment arm subjects may not be entered prior to receipt of the rapid, sputum - based molecular pyrazinamide resistance screening test result showing they are sensitive to pyrazinamide. 9. Having participated in other clinical trials with investigational agents within 8 weeks prior to trial start or currently enrolled in an investigational trial. 10. Subjects with any of the following at screening (per measurements and reading done by Central Electrocardiogram (ECG) where applicable): * Cardiac arrhythmia requiring medication; * Prolongation of QT/QTc interval with QTcF (Fridericia correction) \>450 ms; * History of additional risk factors for Torsade de Pointes, (e.g., heart failure, hypokalemia, family history of Long QT Syndrome); * Any clinically significant ECG abnormality, in the opinion of the investigator. 11. Unstable Diabetes Mellitus which required hospitalization for hyper- or hypo-glycaemia within the past year prior to start of screening. Specific Treatments 12. Previous treatment with PA-824 as part of a clinical trial. 13. For DS-TB treatment arms: Previous treatment for tuberculosis within 3 years prior to Day (-9 to -1)(Screening). Subjects who have previously received isoniazid prophylactically may be included in the trial as long as that treatment is/was discontinued at least 7 days prior to randomization into this trial. For the MDR-TB Subjects: Previous treatment for MDR-TB, although may have been on a MDR TB treatment regimen for no longer than 7 days at start of screening. Previous treatment for TB includes, but is not limited to, gatifloxacin, amikacin, cycloserine, rifabutin, kanamycin, para-aminosalicylic acid, rifapentine, thioacetazone, capreomycin, quinolones, thioamides, and metronidazole. 14. Any diseases or conditions in which the use of the standard TB drugs or any of their components is contra-indicated, including but not limited to allergy to any TB drug, their component or to the IMP. 15. Use of any drug within 30 days prior to randomisation known to prolong QTc interval (including, but not limited to, amiodarone, amitriptyline, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinacrine, quinidine, sotalol, sparfloxacin, thioridazine). 16. Use of systemic glucocorticoids within one year of start of screening (inhaled or intranasal glucocorticoids are allowed). 17. Subjects recently started or expected to need to start anti-retroviral therapy (ART) within 1 month after randomization. Subjects may be included who have been on ARTs for greater than 30 days prior to start of screening, or who are expected to start ART greater than 30 days after randomization. Laboratory Abnormalities 18. Subjects with the following toxicities at screening as defined by the enhanced Division of Microbiology and Infectious Disease (DMID) adult toxicity table (November 2007), where applicable: * creatinine grade 2 or greater (\>1.5 times upper limit of normal \[ULN\]); * creatinine clearance (CrCl) level less than 30 mLs/min according to the Cockcroft-Gault Formula; * haemoglobin grade 4 (\<6.5 g/dL); * platelets grade 3 or greater (under 50x109 cells/L/ 50 000/mm3); * serum potassium less than the lower limit of normal for the laboratory. This may be repeated once; * aspartate aminotransferase (AST) grade 3 or greater (≥3.0 x ULN) ; * alanine aminotransferase (ALT) grade 3 or greater (≥3.0 x ULN); * alkaline phosphatase (ALP): * grade 4 (\>8.0 x ULN) to be excluded; * grade 3 (≥3.0 - 8.0 x ULN) must be discussed with and approved by the sponsor Medical Monitor; * total bilirubin: * 2.0 x ULN, when other liver functions are in the normal range * 1.50 x ULN when accompanied by any increase in other liver function tests subjects with total bilirubin \> 1.25 x ULN and accompanied by any increase in other liver function tests must be discussed with the sponsor medical monitor before enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | From Day 1 to Month 12. | Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy. A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following end of treatment (EOT), had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or were dying from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required an extension, restart or change of treatment except for reinfection/pregnancy, or failed to complete adequate treatment who were unassessable at 12 months or lost to follow-up/withdrawn before EOT. |
| Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | From Day 1 to Month 12. | Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy. A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following EOT, had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or died from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required a restart or change of treatment because of an unfavorable outcome with or without bacteriological confirmation, ie, on bacteriological, radiographic or clinical grounds. |
Countries
Georgia, Kenya, Malaysia, Philippines, South Africa, Tanzania, Uganda, Zambia
Participant flow
Recruitment details
Adult male and female patients with drug-sensitive (DS) and multi-drug resistant (MDR) smear-positive pulmonary tuberculosis (TB) were recruited into this open-label multicenter study.
Pre-assignment details
Patients were confirmed sputum positive for tubercule bacilli on smear microscopy. DS-TB patients were required to be sensitive to rifampicin and newly diagnosed with pulmonary TB (or untreated for at least 3 years). MDR-TB patients were required to be resistant to rifampicin. Both DS and MDR-TB patients could be sensitive/resistant to isoniazid.
Participants by arm
| Arm | Count |
|---|---|
| DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 100 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24. | 65 |
| DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 4 months during the treatment period (from Day 1 to Week 17). Patients then entered a follow-up period up to Month 24. | 71 |
| DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide Patients with DS-TB were randomized to receive 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24. | 67 |
| DS-TB: 2 Months HRZE / 4 Months HR Patients with DS-TB were randomized to receive 150 mg rifampicin + 75 mg isoniazid + 400 mg pyrazinamide + 275 mg ethambutol combination tablets (HRZE) orally once daily from Weeks 1 to 8 during the treatment period. Patients then received 150 mg rifiampicin + 75 mg isoniazid combination tablets (HR) orally once daily from Weeks 9 to 26 during the treatment period. The daily dose of HRZE and HR was calculated based on patients' weight. Patients then entered a follow-up period up to Month 24. | 68 |
| MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide Patients with MDR-TB received 400 mg moxifloxacin + 200 mg pretomanid (PA-824) + 1500 mg pyrazinamide orally once daily for 6 months during the treatment period (from Day 1 to Week 26). Patients then entered a follow-up period up to Month 24. | 13 |
| Total | 284 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Adverse event/specific toxicity | 4 | 3 | 11 | 2 | 1 |
| Overall Study | Death | 1 | 2 | 1 | 0 | 1 |
| Overall Study | Investigator/sponsor decision | 0 | 2 | 0 | 3 | 1 |
| Overall Study | Late exclusion: pyrazinamide resistance | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Late exclusion: rifampicin resistance | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Lost to Follow-up | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Pregnancy | 0 | 0 | 2 | 0 | 0 |
| Overall Study | Protocol Violation | 0 | 0 | 0 | 2 | 0 |
| Overall Study | Treatment non-compliance | 1 | 0 | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | DS-TB: 2 Months HRZE / 4 Months HR | MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Total |
|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 2 Participants | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 6 Participants |
| Age, Categorical >=65 years | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants |
| Age, Categorical Between 18 and 65 years | 63 Participants | 67 Participants | 65 Participants | 67 Participants | 13 Participants | 275 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 65 Participants | 71 Participants | 67 Participants | 68 Participants | 13 Participants | 284 Participants |
| Race/Ethnicity, Customized Asian | 3 Participants | 6 Participants | 6 Participants | 4 Participants | 0 Participants | 19 Participants |
| Race/Ethnicity, Customized Black or African American | 45 Participants | 49 Participants | 45 Participants | 44 Participants | 8 Participants | 191 Participants |
| Race/Ethnicity, Customized Mixed Race | 8 Participants | 12 Participants | 8 Participants | 13 Participants | 3 Participants | 44 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Other | 6 Participants | 1 Participants | 5 Participants | 3 Participants | 0 Participants | 15 Participants |
| Race/Ethnicity, Customized White | 3 Participants | 3 Participants | 3 Participants | 3 Participants | 2 Participants | 14 Participants |
| Sex: Female, Male Female | 14 Participants | 23 Participants | 23 Participants | 20 Participants | 7 Participants | 87 Participants |
| Sex: Female, Male Male | 51 Participants | 48 Participants | 44 Participants | 48 Participants | 6 Participants | 197 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 65 | 3 / 71 | 3 / 67 | 2 / 68 | 1 / 13 |
| other Total, other adverse events | 61 / 65 | 62 / 71 | 63 / 67 | 62 / 68 | 12 / 13 |
| serious Total, serious adverse events | 3 / 65 | 8 / 71 | 8 / 67 | 3 / 68 | 3 / 13 |
Outcome results
Primary
Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population)
Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy. A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following end of treatment (EOT), had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or were dying from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required an extension, restart or change of treatment except for reinfection/pregnancy, or failed to complete adequate treatment who were unassessable at 12 months or lost to follow-up/withdrawn before EOT.
Time frame: From Day 1 to Month 12.
Population: The MITT population included all randomized patients excluding late screening failures, lost to follow-up/withdrawn patients who were culture negative, pregnancy, accidental death during treatment, death during follow-up without TB relapse evidence, re-infection with new TB strain + missing/contaminated Month 12 sputum sample.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Favorable | 38 Participants |
| DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Unfavorable | 19 Participants |
| DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Favorable | 46 Participants |
| DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Unfavorable | 15 Participants |
| DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Favorable | 43 Participants |
| DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Unfavorable | 13 Participants |
| DS-TB: 2 Months HRZE / 4 Months HR | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Unfavorable | 8 Participants |
| DS-TB: 2 Months HRZE / 4 Months HR | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Favorable | 52 Participants |
| MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Favorable | 10 Participants |
| MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) | Unfavorable | 1 Participants |
95% CI: [-4.13, 23.89]
Primary
Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population)
Patients were classified as having a favorable, unfavorable or unassessable status at 12 months from the start of therapy. A favourable status was a negative culture status at 12 months from start of therapy in patients who had not already been classified as having an unfavorable outcome, and whose last positive culture result was followed by at least 2 negative culture results. Patients with an unfavorable status did not achieve/maintain culture negative status, or previously had culture negative status who following EOT, had 2 positive cultures, or had a positive culture not followed by 2 negative cultures, or died from any cause during treatment (except accidental cause not including suicide), or were dying from TB related causes during follow-up, or required a restart or change of treatment because of an unfavorable outcome with or without bacteriological confirmation, ie, on bacteriological, radiographic or clinical grounds.
Time frame: From Day 1 to Month 12.
Population: The PP population consisted of the MITT population, excluding patients who were lost to follow-up/withdrawn, had modified/extended treatment for reasons other than unfavourable therapeutic response, did not receive adequate amount of allocated study regimen and patients with major protocol deviations, unless already classified as unfavourable.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Favorable | 38 Participants |
| DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Unfavorable | 14 Participants |
| DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Favorable | 46 Participants |
| DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Unfavorable | 11 Participants |
| DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Favorable | 43 Participants |
| DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Unfavorable | 4 Participants |
| DS-TB: 2 Months HRZE / 4 Months HR | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Unfavorable | 1 Participants |
| DS-TB: 2 Months HRZE / 4 Months HR | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Favorable | 52 Participants |
| MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Favorable | 10 Participants |
| MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Per Protocol [PP] Population) | Unfavorable | 0 Participants |
95% CI: [-2.15, 15.4]